{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-031923","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.422380+00:00","generated_at":"2026-05-31T20:29:40.491654+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo Therapeutics appoints Mittie Doyle, M.D., as CMO; grants 234,000-share option","bullets":["Dr. Doyle, former CMO at Aro Biotherapeutics, brings over 20 years of pharma/biotech experience.","She will lead Phase 2 LOTUS Trial for AVTX-009 in hidradenitis suppurativa.","Base salary of $500,000, target bonus of 40%, and inducement stock option for 234,000 shares vesting over 4 years.","Severance includes nine months' salary (12 months post-change-in-control), full option vesting, and COBRA.","Appointment effective July 15, 2024; employment agreement filed as Exhibit 10.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-031923","json":"https://secwatch.observer/filing/0001628280-24-031923.json","markdown":"https://secwatch.observer/filing/0001628280-24-031923.md","text":"https://secwatch.observer/filing/0001628280-24-031923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/0001628280-24-031923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/avtx-20240715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:29:40.491654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"332bff5249","claim":"Mittie Doyle was appointed as Chief Medical Officer at Avalo Therapeutics, Inc..","evidence_excerpt":"On July 16, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Mittie Doyle, M.D., FACR, as Chief Medical Officer, effective July 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024031923/0001628280-24-031923-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}